Skip to main content
Erschienen in: World Journal of Urology 12/2015

01.12.2015 | Original Article

Loss of AQP3 protein expression is associated with worse progression-free and cancer-specific survival in patients with muscle-invasive bladder cancer

verfasst von: Peter Rubenwolf, Christian Thomas, Stefan Denzinger, Arndt Hartmann, Maximilian Burger, Nikolaos T. Georgopoulos, Wolfgang Otto

Erschienen in: World Journal of Urology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Urothelial carcinoma has recently been shown to express several aquaporins (AQP), with AQP3 being of particular interest as its expression is reduced or lost in tumours of higher grade and stage. Loss of AQP3 expression was associated with worse progression-free survival (PFS) in patients with pT1 bladder cancer. The objective of this study was to investigate the prognostic value of AQP3 expression in patients with muscle-invasive bladder carcinoma (MIBC).

Methods

Retrospective single-centre analysis of the oncological outcome of patients following radical cystectomy (Cx) due to MIBC. Immunohistochemistry was used to assess AQP3 protein expression in 100 Cx specimens. Expression levels of AQP3 were related to clinicopathological variables. The impact of biomarker expression on progression-free, cancer-specific and overall survival was determined by multivariate Cox regression analysis (MVA).

Results

High expression of AQP3 by the tumour was associated with a statistically significantly improved PFS (75 vs. 19 %, p = 0.043) and CSS (75 vs. 18 %, p = 0.030) and, alongside lymph node involvement, was an independent predictor of PFS (HR 2.871, CI 1.066–7.733, p = 0.037), CSS (HR 3.325, CI 1.204–8.774, p = 0.019) and OS (HR 2.001, CI 1.014–3.947) in MVA.

Conclusions

Although the results of the study would be strengthened by a larger, more appropriately powered, prospective, multi-institutional study, our findings strongly suggest that AQP3 expression status may represent an independent predictor of PFS and CSS in MIBC and may help select patients in need for (neo-)adjuvant chemotherapy.
Literatur
1.
Zurück zum Zitat Green DA, Rink M, Xylinas E et al (2013) Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol 189(4):1214–1221CrossRefPubMed Green DA, Rink M, Xylinas E et al (2013) Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol 189(4):1214–1221CrossRefPubMed
2.
Zurück zum Zitat Rubenwolf PC, Georgopoulos NT, Clements LA et al (2009) Expression and localisation of aquaporin water channels in human urothelium in situ and in vitro. Eur Urol 56(6):1013–1023CrossRefPubMed Rubenwolf PC, Georgopoulos NT, Clements LA et al (2009) Expression and localisation of aquaporin water channels in human urothelium in situ and in vitro. Eur Urol 56(6):1013–1023CrossRefPubMed
3.
Zurück zum Zitat Rubenwolf PC, Georgopoulos NT, Kirkwood LA, Baker SC, Southgate J (2012) Aquaporin expression contributes to human transurothelial permeability in vitro and is modulated by NaCl. PLoS ONE 7(9):e45339PubMedCentralCrossRefPubMed Rubenwolf PC, Georgopoulos NT, Kirkwood LA, Baker SC, Southgate J (2012) Aquaporin expression contributes to human transurothelial permeability in vitro and is modulated by NaCl. PLoS ONE 7(9):e45339PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat Saadoun S, Papadopoulos MC, Hara-Chikuma M, Verkman AS (2005) Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature 434(7034):786–792CrossRefPubMed Saadoun S, Papadopoulos MC, Hara-Chikuma M, Verkman AS (2005) Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature 434(7034):786–792CrossRefPubMed
5.
Zurück zum Zitat Rubenwolf PC, Otto W, Denzinger S, Hofstadter F, Wieland W, Georgopoulos NT (2014) Expression of aquaporin water channels in human urothelial carcinoma: correlation of AQP3 expression with tumour grade and stage. World J Urol 32(4):991–997CrossRefPubMed Rubenwolf PC, Otto W, Denzinger S, Hofstadter F, Wieland W, Georgopoulos NT (2014) Expression of aquaporin water channels in human urothelial carcinoma: correlation of AQP3 expression with tumour grade and stage. World J Urol 32(4):991–997CrossRefPubMed
6.
Zurück zum Zitat Otto W, Rubenwolf PC, Burger M et al (2012) Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer. BMC Cancer 12:459PubMedCentralCrossRefPubMed Otto W, Rubenwolf PC, Burger M et al (2012) Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer. BMC Cancer 12:459PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Cheng L, Davison DD, Adams J et al (2014) Biomarkers in bladder cancer: translational and clinical implications. Crit Rev Oncol Hematol 89(1):73–111CrossRefPubMed Cheng L, Davison DD, Adams J et al (2014) Biomarkers in bladder cancer: translational and clinical implications. Crit Rev Oncol Hematol 89(1):73–111CrossRefPubMed
8.
Zurück zum Zitat Frantzi M, Makridakis M, Vlahou A (2012) Biomarkers for bladder cancer aggressiveness. Curr Opin Urol 22(5):390–396CrossRefPubMed Frantzi M, Makridakis M, Vlahou A (2012) Biomarkers for bladder cancer aggressiveness. Curr Opin Urol 22(5):390–396CrossRefPubMed
9.
Zurück zum Zitat Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG (2012) Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 61(5):1039–1047CrossRefPubMed Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG (2012) Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 61(5):1039–1047CrossRefPubMed
10.
Zurück zum Zitat Burger M, Mulders P, Witjes W (2012) Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire. Eur Urol 61(5):1070–1071CrossRefPubMed Burger M, Mulders P, Witjes W (2012) Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire. Eur Urol 61(5):1070–1071CrossRefPubMed
11.
Zurück zum Zitat Kusayama M, Wada K, Nagata M et al (2011) Critical role of aquaporin 3 on growth of human esophageal and oral squamous cell carcinoma. Cancer Sci 102(6):1128–1136CrossRefPubMed Kusayama M, Wada K, Nagata M et al (2011) Critical role of aquaporin 3 on growth of human esophageal and oral squamous cell carcinoma. Cancer Sci 102(6):1128–1136CrossRefPubMed
12.
Zurück zum Zitat Huang Y, Zhu Z, Sun M et al (2010) Critical role of aquaporin-3 in the human epidermal growth factor-induced migration and proliferation in the human gastric adenocarcinoma cells. Cancer Biol Ther 9(12):1000–1007CrossRefPubMed Huang Y, Zhu Z, Sun M et al (2010) Critical role of aquaporin-3 in the human epidermal growth factor-induced migration and proliferation in the human gastric adenocarcinoma cells. Cancer Biol Ther 9(12):1000–1007CrossRefPubMed
13.
Zurück zum Zitat Jablonski EM, Mattocks MA, Sokolov E et al (2007) Decreased aquaporin expression leads to increased resistance to apoptosis in hepatocellular carcinoma. Cancer Lett 250(1):36–46PubMedCentralCrossRefPubMed Jablonski EM, Mattocks MA, Sokolov E et al (2007) Decreased aquaporin expression leads to increased resistance to apoptosis in hepatocellular carcinoma. Cancer Lett 250(1):36–46PubMedCentralCrossRefPubMed
Metadaten
Titel
Loss of AQP3 protein expression is associated with worse progression-free and cancer-specific survival in patients with muscle-invasive bladder cancer
verfasst von
Peter Rubenwolf
Christian Thomas
Stefan Denzinger
Arndt Hartmann
Maximilian Burger
Nikolaos T. Georgopoulos
Wolfgang Otto
Publikationsdatum
01.12.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 12/2015
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-015-1574-8

Weitere Artikel der Ausgabe 12/2015

World Journal of Urology 12/2015 Zur Ausgabe

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.